Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
How Pharmaceutical Tariffs Will Affect US Health Care Costs

How Pharmaceutical Tariffs Will Affect US Health Care Costs

Sep 26, 2025 | Analysis

Tariffs on pharmaceuticals are under consideration following a Section 232 investigation into imports of medicines and active pharmaceutical ingredients (APIs).

MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors

MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors

Sep 17, 2025 | Analysis

Today, MGA released a report in collaboration with the HDA measuring the economic impact of healthcare distributors in the United States.

MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition

MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition

Jul 14, 2025 | Analysis

This week, MGA released a new white paper by Alex Brill and Christy Robinson looking at the long-term effects of Medicare price negotiations on drug competition

The 340B Program’s Negative Impact on Pharmaceutical Innovation

The 340B Program’s Negative Impact on Pharmaceutical Innovation

Jun 5, 2025 | Analysis

As the Department of Health and Human Services considers changes to the federal 340B drug program, including switching mandatory drug manufacturer contributions from discounts to rebates, it is important for policymakers to recognize the myriad concerns with this program.

New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade

New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade

Mar 5, 2025 | Analysis

Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.

Implications of Cannabis Legalization for the US Federal Budget

Implications of Cannabis Legalization for the US Federal Budget

Aug 14, 2024 | Analysis

While the details of future federal legislation and executive actions to legalize, regulate, and tax cannabis remain unknown, such policies could have significant impacts on the federal budget.

« Older Entries
  • Analysis (53)
  • Books (3)
  • Commentary (15)
  • Events (21)
  • Interviews (60)
  • News (55)
  • Op-Eds (97)
  • Press Releases (4)
  • Testimony (21)
  • How Pharmaceutical Tariffs Will Affect US Health Care Costs
    How Pharmaceutical Tariffs Will Affect US Health Care CostsSeptember 26, 2025
  • Quantifying the economic impact of healthcare distributors
    MGA Releases New Report Quantifying the Economic Impact of Healthcare DistributorsSeptember 17, 2025
  • Unsung Hero of the OBBBA
    The Unsung Hero of the OBBBA: Permanent ExpensingAugust 20, 2025
  • Alex Brill Interviewed by Biosimilars Review & Report
    Alex Brill Interviewed by Biosimilars Review & ReportAugust 6, 2025
  • Medicare Price Negotiations and Drug Competition
    MGA Releases New White Paper on Medicare Price Negotiations and Drug CompetitionJuly 14, 2025
  • effects of 304B
    The 340B Program’s Negative Impact on Pharmaceutical InnovationJune 5, 2025
  • a conversation on tax reform
    A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax ReformMarch 5, 2025
  • US Biosimilars Market
    New MGA Paper Identifies Barriers to US Biosimilar Success in the Second DecadeMarch 5, 2025
  • Congress on the Brink of Disrupting the PBM Market
    Congress on the Brink of Disrupting the PBM MarketJanuary 27, 2025
  • Raising the Salt Cap Would Increase Tax Complexity
    Raising the Salt Cap Would Increase Tax ComplexityJanuary 13, 2025
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact